Corcept Therapeutics Inc. Stock
The price for the Corcept Therapeutics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.300 (-0.760%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 95 € there is potential for a 140.99% increase which would mean more than doubling the current price of 39.42 € for Corcept Therapeutics Inc..
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | -0.760% | -1.682% | 9.605% | -38.914% | -43.595% | 89.069% | 93.819% |
| Rockwell Medical Inc. | 0.680% | -5.195% | -17.700% | -28.711% | 7.908% | -63.057% | -91.198% |
| Pacira Pharmaceuticals | 0.970% | -0.962% | 1.980% | -7.207% | -4.630% | -48.756% | -60.762% |
| Savara Inc. | 3.070% | -15.207% | -8.341% | 49.029% | -21.830% | 158.938% | 154.172% |
Comments
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target lowered by HC Wainwright from $67.00 to $60.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $105.00 to $67.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
News
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately